Veozah Dosing Recommendations
The recommended dose of Veozah (fezolinetant) is 45 mg taken orally once daily, with or without food, at approximately the same time each day. 1
Administration Details
- Tablet preparation: Swallow tablets whole with liquids—do not cut, crush, or chew 1
- Timing flexibility: If a dose is missed, take it as soon as possible unless less than 12 hours remain before the next scheduled dose. In that case, skip the missed dose and resume the regular schedule the following day 1
- No dose titration: Unlike many medications, fezolinetant does not require dose escalation—the therapeutic dose is 45 mg from initiation 1, 2, 3
Critical Pre-Treatment Requirements
Before starting Veozah, you must obtain baseline hepatic laboratory tests including ALT, AST, alkaline phosphatase, and total/direct bilirubin. 1
Do NOT initiate treatment if:
- ALT or AST ≥ 2 × upper limit of normal (ULN)
- Total bilirubin ≥ 2 × ULN 1
Mandatory Monitoring Schedule
Perform follow-up liver function tests at specific intervals:
- Monthly for the first 3 months (months 1,2, and 3)
- At 6 months
- At 9 months 1
This monitoring schedule is non-negotiable given the FDA's boxed warning regarding hepatotoxicity risk. Real-world data shows liver-related adverse events typically occur within the first 100 days of treatment, with median onset at 38 days 4.
Contraindications to Treatment
Absolute contraindications include:
- Known cirrhosis
- Severe renal impairment or end-stage renal disease
- Concomitant use with CYP1A2 inhibitors 1
When to Stop Treatment
Discontinue immediately if:
- Transaminase elevations > 5 × ULN
- Transaminase elevations > 3 × ULN AND total bilirubin > 2 × ULN
- Patient develops symptoms suggesting liver injury (new fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale stools, dark urine, or abdominal pain) 1
If transaminase elevations exceed 3 × ULN but don't meet discontinuation criteria, increase monitoring frequency until resolution 1.
Clinical Efficacy Timeline
Patients can expect symptom improvement rapidly—clinical trials demonstrated significant reductions in vasomotor symptom frequency and severity as early as week 1, with sustained benefits through 52 weeks 2, 3. The medication showed reductions of 2-3 hot flashes per day compared to placebo by week 4, with continued improvement through week 12 2, 3.
Important Safety Considerations
Real-world pharmacovigilance data reveals a broader hepatic safety profile than initially recognized in clinical trials, including cholestatic patterns beyond simple transaminase elevation 4. The hepatotoxicity risk necessitates the boxed warning and strict monitoring protocol. Postmarketing reports documented drug-induced liver injury with elevations in ALT, AST, alkaline phosphatase, and bilirubin occurring within 40 days of treatment initiation 1.